TSHR signal mediation partly depends on functional IGF-1R, and the human IGF-1R inhibitory monoclonal antibody teprotumumab is a breakthrough advancement in TAO treatment (Smith et al., 2017; Douglas et al., 2020). This evidence concerns the gene TSHR and thromboangiitis obliterans.